Skip to content

Trial · Interventional

CompletedPhase 1Registry data

Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

NCTNCT01507311 (opens ClinicalTrials.gov in a new tab)Other idNN2211-1219
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 1
Enrollment
11 participants (actual)
Sponsor
Novo Nordisk A/S · Industry
Design
Randomized · Double masking
Countries
1 country

Denmark

Start
Sept 1999
Primary completion
Dec 1999
Completion
Dec 1999
First posted
10 Jan 2012 (estimated)
Last update posted
24 Jan 2017 (estimated)
Conditions
Diabetes · Diabetes Mellitus, Type 2

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
19992000
  1. Ph 1

    Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

    NCT01507311

    Sept 1999 to Dec 1999

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This trial is conducted in Europe. The aim of this trial is to assess the effect of NNC 90-1170 (liraglutide) on pulsatile insulin secretion and insulin secretion after a standard meal in subjects with type 2 diabetes.

Interventions

  • liraglutideDrug
  • placeboDrug

Arms2

  • Experimental

    NNC 90-1170

  • Placebo comparator

    Placebo

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Insulin secretory burst mass

Secondary outcomes(5)

  1. Insulin secretory pulse mass, amplitude, frequency and regularity

  2. Insulin secretion

  3. Glucagon response

  4. Gastric emptying rate

  5. Adverse events

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2002

11 results

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

Juhl et al. 2002Diabetescited by 201

PMID 11812750DOI 10.2337/diabetes.51.2.424PUB-11812750

Rights unknown11 results
Source linkSee results (11)

Eligibility

Who could join, as posted.

Sex
All
Age
from 30 Years up to 75 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Diagnosed with type 2 diabetes, either newly diagnosed with at least two months of diet treatment, or in current OHA (oral hypoglycaemic agent) treatment with stable dose for at least six months * BMI (Body Mass Index) between 24 and 35 kg/m\^2 (both inclusive) * Fasting plasma glucose between 6 and 15 mmol/l (both inclusive) * Anti-GAD (glutamic acid decarboxylase) negative Exclusion Criteria: * Known or suspected allergy to trial product or related products * Receipt of any investigational drug within three months prior to this trial * Recurrent severe hypoglycaemia as judged by the investigator * Cardiac disease or any clinically significant abnormal ECG (electrocardiogram) * Use of any drug (except oral hypoglycaemic agents (OHAs)) which in the investigator's opinion could interfere * with the blood glucose level (i.e., insulin, systemic corticosteroids, thiazides) * Liver or renal disease

PepBank is a research reference. Talk to a doctor before you use any peptide.